2026 Drug Development Insurance Coverage and Processing 
Pharmaceutical Technology
JULY 14, 2025
Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. A decision by the FDA is expected in H1 2026. MAXSHOT.PL via Shutterstock.
Pharmaceutical Technology
JULY 9, 2025
JCR values its partnership with Alexion, and we are pleased to build on the collaboration we have developed over the years.” The financial impact of this agreement on JCR’s consolidated results for the fiscal year ending 31 March 2026 has already been included in the current earnings forecast.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 14, 2025
The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit.” Efforts are underway to work with the FDA to resolve them.
Pharmaceutical Technology
JULY 30, 2025
The future of DMD drug development now hinges on who steps into the role and how the FDA navigates this high-profile therapeutic area.” ” The public playout of DMD treatment developers with the FDA is not only impacting biopharma share prices but also raising concerns about the agency’s internal operations.
Pharmaceutical Technology
JULY 17, 2025
Sarepta Therapeutics is set to cut 500 jobs as part of its restructuring and pipeline prioritisation plan, which is expected to result in annual cash cost savings of $120m in 2026. With its pipeline reprioritisation, the company anticipates delivering $300m in annual non-personnel cost savings from 2026.
Expert insights. Personalized for you.
Let's personalize your content